Neuroendocrine Tumor Omic Gene Cluster Analysis Amplifies the Prognostic Accuracy of the NETest.
Published on Jan 1, 2021in Neuroendocrinology4.271
· DOI :10.1159/000508573
BACKGROUND: The NETest is a multi-gene assay comprising 51 circulating neuroendocrine tumor specific transcripts. The quotient of the 51-gene assay is based upon an ensemble of machine learning algorithms. Eight cancer hallmarks or "omes" (apoptome, epigenome, growth factor signalome, metabolome, proliferome, plurome, secretome SSTRome) represent 29 genes. The NETest is an accurate diagnostic (>90%) but its prognostic utility has not been assessed. In this study, we describe expansion of the NETest omic cluster components and demonstrate that integration amplifies NETest prognostic accuracy. METHODS: Group 1 (n=222; including stable disease (SD: n=164), progressive disease (PD: n=76) and controls (n=139)). Group 2: NET Registry #NCT02270567 (n=88, prospective samples (SD n=54 and PD n=34) with up to 24 months follow-up. We used PubMed literature review, interactomic analysis, non-parametric testing, Kaplan-Meier survival curves and Chi2 analyses to inform and define the prognostic significance of NET genomic "hallmarks". RESULTS: 2020 Analyses: In-depth analyses of 47 NETest genes identified a further 6 omes: fibrosome, inflammasome, metastasome, NEDome, neurome and TFome. Group 1 analysis: Twelve omes, excluding the inflammasome and apoptome, were significantly (p 2) versus SD. Group 2. All these 7 omes were upregulated. In PD, they were significantly more elevated (p 40) including the fibrosome/NEDome predicted PD development within 3 months (100%). Using decision tree analysis to integrate the 4 omes (epigenome, metastasome, fibrosome and NEDome) with the NETest score generated an overall prognostic accuracy of 93%. CONCLUSIONS: Examination of NETest omic gene cluster analysis identified 5 additional clinically-relevant cancer hallmarks. Identification of 7 omic clusters (septet) provides a molecular pathological signature of disease progression. The integration of the quartet (epigome, fibrosome, metastasome, NEDome) and the NETest score yielded a 93% accuracy in the prediction of future disease status.